Table 1 Characteristics of the studies included in the meta-analysis.
First author (year of publication) | Total patients (DIBH/FB) | Clinical stage | Median age (years) | Prescription dose (Gy)/fractions (F) | Plan types | Study type | NOS score |
|---|---|---|---|---|---|---|---|
Angela 201721 | 64 (32/32) | NA | NA | 50 Gy/25 F | 3D-CRT | Retrospective | 6 |
Bruzzaniti 201327 | 16 (8/8) | NA | 51 | 50 Gy/25 F | 3D-CRT | Retrospective | 7 |
Chi. F. 201526 | 62 (31/31) | I or II | 39.5 | 50 Gy/25 F | IMRT | Retrospective | 8 |
Hepp 201525 | 40 (20/20 ) | pTis–pT1 pN0 | NA | 50 Gy/25 f | 3D-CRT | Retrospective | 7 |
Jensen 201723 | 44 (22/22) | pT1-2N0M0 | 58 | 50 Gy/25 f | 3D-CRT | Retrospective | 7 |
Lastrucci 201722 | 46 (23/23) | NA | NA | 50 Gy/25 f | 3D-CRT | Retrospective | 7 |
Corradini 201729 (3D-CRT group) | 20 (10/10) | NA | NA | 50 Gy/25 f | 3D-CRT | Retrospective | 7 |
Corradini 201729 (VMAT group) | 20 (10/10) | NA | NA | 50 Gy/25 f | VMAT | Retrospective | 7 |
Pham 201624 (IMRT group) | 30 (15/15) | NA | NA | 50 Gy/25 f | IMRT | Retrospective | 6 |
Pham 201624 (VMAT group) | 30 (15/15) | NA | NA | 50 Gy/25 f | VMAT | Retrospective | 6 |
Sakyanun 202019 | 50 (25/25) | NA | NA | 50 Gy/25 f | IMRT | Retrospective | 6 |
Vikström 201128 | 34 (17/17) | NA | 60 | 50 Gy/25 f | 3D-CRT | Retrospective | 6 |
Yamauchi 20208 | 170 (85/85) | NA | 49.3 | 50 Gy/25 f | IMRT | Retrospective | 7 |
Zhao-Feng 201820 (3D-CRT Group) | 44 (22/22) | NA | 48 | 50 Gy/25 f | 3D-CRT | Retrospective | 7 |
Zhao-Feng 201820 (IMRT group) | 44 (22/22) | NA | 48 | 50 Gy/25 f | IMRT | Retrospective | 7 |
